Literature DB >> 10480207

Visual field constriction is not limited to children treated with vigabatrin.

G Wohlrab1, E Boltshauser, B Schmitt, S Schriever, K Landau.   

Abstract

Vigabatrin (GVG) is widely used in the treatment of complex partial seizures and infantile spasms. Persistent visual field constriction associated with GVG therapy in adults was reported as a rare but serious side-effect. Visual field examination in children is more difficult because of a lack of cooperation among very young or mentally handicapped patients. We performed Goldmann perimetry in 12 of 153 patients treated with GVG as mono- or as add-on therapy. The others would not cooperate, and two adolescents refused the examination. For comparison, we examined 12 age-matched patients with complex partial or generalized epilepsy who had never taken GVG. In five of 12 GVG-treated patients, and in one of the control group, we found a concentric visual field constriction. All patients were subjectively asymptomatic. The GVG-treated patients had taken the drug in combination with valproic acid (VPA) or oxcarbazepine (OCB). In four patients, GVG treatment was already stopped at the time of the ophthalmologic examination. Three patients had intracerebral lesions that could not account for the pathologic perimetric findings. The single patient from the control group with concentric visual field constriction had an absence epilepsy, treatment being performed with VPA and lamotrigine (LTG). In conclusion, GVG has a causal but not unique connection with visual field constriction in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480207     DOI: 10.1055/s-2007-973477

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  12 in total

Review 1.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

4.  The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin.

Authors:  Carol A Westall; William J Logan; Kim Smith; J Raymond Buncic; Carole M Panton; Mohamed Abdolell
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

Review 5.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 6.  Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.

Authors:  Rima Nabbout; Mathieu Kuchenbuch; Catherine Chiron; Paolo Curatolo
Journal:  CNS Drugs       Date:  2021-08-21       Impact factor: 5.749

7.  Visual field defects in pediatric patients on vigabatrin monotherapy.

Authors:  Francisco J Ascaso; María J Lopez; José A Mauri; José A Cristobal
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

8.  Vigabatrin and visual field defects in pediatric epilepsy patients.

Authors:  Su Jeong You; HyoSook Ahn; Tae-Sung Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 9.  Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Authors:  M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

Review 10.  Visual field defects and other ophthalmological disturbances associated with vigabatrin.

Authors:  S J Spence; R Sankar
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.